Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a heterogeneous entity with wide variation in clinical course and prognosis. Histopathological analysis of renal biopsies is essential for assessing disease activity and chronicity, predicting treatment response, and improving renal prognosis. In this context, the ANCA renal risk score is presented as a viable alternative to the Berden classification. Compared with this classification, the ANCA renal risk score includes the extraglomerular component, which contributes greater predictive capacity. The same has been validated in randomized clinical trials in the European population, but there is no perspective for Latin America.
Retrospective observational cohort study, included 34 patients diagnosed with ANCA-associated vasculitis with renal involvement, 26 underwent renal biopsy, to whom the parameters of the ARRS score were applied, during the period from June 2021 to December 2024. Statistical analysis was performed in the SPSS version 25 program, to validate the ARRS score and determine the predictive capacity compared to the Berden classification.
De los 26 pacientes (61.5%) fueron mujeres, (38.4%) hombres. Después del tratamiento inmunosupresor a base de metilprednisolona y ciclofosfamida intravenosa (92.3%) presentaron remisión (p = 0.06). La recaída renal se evidenció en (15.3%) (p = 0.04), de los cuales (23%) requirieron hemodiálisis al momento del diagnóstico; después de 42 meses del período de estudio (34.6%) progresaron a (ERT) con dependencia posterior a terapia de reemplazo renal (TRR). Del total de pacientes (11.5%) requirieron tratamiento de reinducción (p = 0.08) y (18%) fallecieron durante el período de estudio (p = 0.76) (Tabla 1) . De acuerdo con la clasificación de Berden se clasificaron: focal (15.3%), mixto (46.1%), semilunar (3.8%) y patrón esclerótico (50%). Respecto al puntaje de riesgo renal (ANCA) se asignaron: riesgo bajo (19,2%), riesgo medio (30%) y riesgo alto (50%). (Tabla 2) En el modelo de regresión logística multivariante, el puntaje (ARRS) se asoció con 1,88 veces la probabilidad de progresar a (ESRD) (OR 1,88; p = 0,01, IC 95% 1,16-3,08), en contraste con la clasificación de Berden con una probabilidad de 1,38 veces de presentar este desenlace. (Tabla 3) La capacidad discriminatoria de la escala ARRS para predecir la progresión a enfermedad renal crónica terminal (ESRD) a los 42 meses fue de (AUC = 0,97), con una sensibilidad del 95% y una especificidad del 100% (p = 0,03) (Figura 1) , mientras que la clasificación de Berden presentó una menor capacidad predictiva (AUC = 0,46), con una sensibilidad del 22% y una especificidad del 69% (p = 0,82). (Figura 2)
The ARRS score is established as a valuable tool for predicting treatment response and risk of progression to ESRD in patients with ANCA-associated vasculitis. This allows for improved treatment planning and a more personalized approach based on individual patient goals.
